Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTX-HSA-biotin
- Development stage
- Preclinical
- Lead developer
- Tehran University of Medical Sciences
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
DTX-HSA-biotin is a targeted nanoparticle conjugate consisting of the chemotherapeutic agent docetaxel (DTX) covalently bound to human serum albumin (HSA) and functionalized with biotin as a targeting ligand. Developed by researchers at the Tehran University of Medical Sciences, this conjugate is designed to improve the water solubility of docetaxel and enhance its tumor-specific delivery. The biotin moiety targets the sodium-dependent multivitamin transporter (SMVT), which is overexpressed on various cancer cells, facilitating receptor-mediated endocytosis and intracellular drug release. In preclinical models of breast cancer, DTX-HSA-biotin demonstrated superior cytotoxicity and tumor reduction compared to free docetaxel.
- Other names
- biotin-HSA-DTXbiotin-decorated human serum albumin nanoparticles of docetaxeldocetaxel-human serum albumin-biotin conjugateDTX-HSA-biotin conjugate
02
Targets
SLC5A6 (Sodium-dependent multivitamin transporter)SPARC (Secreted protein acidic and rich in cysteine)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on DTX-HSA-biotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTX-HSA-biotin.